AU2019338674B2 - Bispecific antibody targeting IL-1R1 and NLRP3 - Google Patents

Bispecific antibody targeting IL-1R1 and NLRP3

Info

Publication number
AU2019338674B2
AU2019338674B2 AU2019338674A AU2019338674A AU2019338674B2 AU 2019338674 B2 AU2019338674 B2 AU 2019338674B2 AU 2019338674 A AU2019338674 A AU 2019338674A AU 2019338674 A AU2019338674 A AU 2019338674A AU 2019338674 B2 AU2019338674 B2 AU 2019338674B2
Authority
AU
Australia
Prior art keywords
antibody
nlrp3
seq
modulator
glaucoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019338674A
Other languages
English (en)
Other versions
AU2019338674A1 (en
Inventor
Victoria MCGILLIGAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ulster
Original Assignee
University of Ulster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Ulster filed Critical University of Ulster
Publication of AU2019338674A1 publication Critical patent/AU2019338674A1/en
Application granted granted Critical
Publication of AU2019338674B2 publication Critical patent/AU2019338674B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019338674A 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3 Active AU2019338674B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815045.8 2018-09-14
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3
PCT/EP2019/074744 WO2020053446A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3

Publications (2)

Publication Number Publication Date
AU2019338674A1 AU2019338674A1 (en) 2021-04-22
AU2019338674B2 true AU2019338674B2 (en) 2026-02-05

Family

ID=64013420

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019338674A Active AU2019338674B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3
AU2019338955A Active AU2019338955B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019338955A Active AU2019338955B2 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting IL-1R1 and NLRP3

Country Status (7)

Country Link
US (2) US12227579B2 (enExample)
EP (3) EP4778533A2 (enExample)
JP (3) JP7645544B2 (enExample)
CN (2) CN112996564A (enExample)
AU (2) AU2019338674B2 (enExample)
GB (1) GB201815045D0 (enExample)
WO (2) WO2020053446A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
EP4268834A4 (en) * 2020-12-28 2024-10-16 MD Healthcare Inc. Composition for preventing or treating eye diseases comprising micrococcus luteus-derived extracellular vesicles
US20250382341A1 (en) * 2022-12-30 2025-12-18 The Regents Of The University Of California Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
CN120535627B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061005A2 (en) 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
WO2007081982A2 (en) 2006-01-10 2007-07-19 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
FR2937339B1 (fr) 2008-10-21 2013-02-15 Univ Bourgogne Procede de detection de la maladie atheromateuse.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2011109459A2 (en) 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2013007763A1 (en) 2011-07-12 2013-01-17 Universität Zürich MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
WO2013113615A1 (en) * 2012-02-03 2013-08-08 F. Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
WO2013119673A1 (en) 2012-02-06 2013-08-15 University Of Miami Innate immune proteins as biomarkers for cns injury
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20160354437A1 (en) 2014-02-13 2016-12-08 Northwestern University Compositions and methods for modulation of immune response
CN104258398B (zh) * 2014-10-14 2017-12-22 中国科学技术大学 Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途
WO2017079352A2 (en) 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
US20200115358A1 (en) * 2016-03-11 2020-04-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
US10041044B2 (en) * 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANG FENG ET AL: "NLRP3 inflammasome in retinal ganglion cell loss in optic neuropathy", NEURAL REGENERATION RESEARCH, vol. 11, no. 7, 1 July 2016 (2016-07-01), CN, pages 1077 - 1078 *

Also Published As

Publication number Publication date
WO2020053447A1 (en) 2020-03-19
EP3849661A1 (en) 2021-07-21
CN112996563A (zh) 2021-06-18
JP7517702B2 (ja) 2024-07-17
JP2022500457A (ja) 2022-01-04
US12227579B2 (en) 2025-02-18
EP3849662A1 (en) 2021-07-21
JP7645544B2 (ja) 2025-03-14
JP2024125385A (ja) 2024-09-18
GB201815045D0 (en) 2018-10-31
AU2019338955B2 (en) 2026-03-19
US20220041739A1 (en) 2022-02-10
CN112996564A (zh) 2021-06-18
JP2022500455A (ja) 2022-01-04
US12264201B2 (en) 2025-04-01
WO2020053446A1 (en) 2020-03-19
AU2019338955A1 (en) 2021-04-15
EP4778533A2 (en) 2026-07-22
AU2019338674A1 (en) 2021-04-22
US20220033507A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US12227579B2 (en) Bispecific antibody targeting IL-1R1 and NLPR3
TWI747922B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP2023093528A (ja) 抗ｔｒｅｍ２抗体及びその使用方法
AU2018370279B2 (en) Antibodies to a-synuclein and uses thereof
CN110267985B (zh) 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
JP2022101694A (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
TWI547501B (zh) 用於中和血管內皮生長因子之重組單株抗體vNAR
KR20230109785A (ko) 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
JP2022514290A (ja) 改変抗体ｆｃおよび使用方法
CA3203202A1 (en) Nanobody to glycoprotein vi
US20230183325A1 (en) Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
HK40022840B (en) ANTIBODIES TO α‐SYNUCLEIN AND USES THEREOF
HK1229346A1 (en) Vnar recombinant monoclonal antibodies that neutralize vascular endophelial growth factor vegf

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)